Novartis Gleevec Drug Interaction Program Is Phase IV For GIST Approval
Executive Summary
Novartis will develop a Gleevec physician-patient drug interaction education program as a Phase IV commitment associated with FDA's approval of the product for treatment of gastrointestinal stromal tumors
You may also be interested in...
Bear Stearns Healthcare Conference In Brief
One Swiss pharma company?: Novartis continues "to indicate to Roche that it might be a good idea for us to sit down and talk and I think as late as last Sunday, the Roche CEO continues to say that it's absolutely out of the question and not on the table," General Manager Kurt Graves says during Bear Stearns healthcare conference in New York City Sept. 17. "I would say it's remained consistent for over a year." Novartis' purchase of a 20% stake in Roche a year ago sparked rumors that Novartis was interested in partnering with its Swiss neighbor (1"The Pink Sheet" May 14, 2001, p. 11)...
Bear Stearns Healthcare Conference In Brief
One Swiss pharma company?: Novartis continues "to indicate to Roche that it might be a good idea for us to sit down and talk and I think as late as last Sunday, the Roche CEO continues to say that it's absolutely out of the question and not on the table," General Manager Kurt Graves says during Bear Stearns healthcare conference in New York City Sept. 17. "I would say it's remained consistent for over a year." Novartis' purchase of a 20% stake in Roche a year ago sparked rumors that Novartis was interested in partnering with its Swiss neighbor (1"The Pink Sheet" May 14, 2001, p. 11)...
Novartis Gleevec For Leukemia Will Be In Pharmacies By Mid-May
Novartis' chronic myeloid leukemia therapy Gleevec will be available in pharmacies by the time oncologists return from the American Society of Clinical Oncology May 12-15 meeting.